MAYNE PHARMA — Patent Portfolio
1 drug with active patents · 38 active patents · 0 expired · 0 biologics with BPCIA exclusivity
Verdict MAYNE PHARMA's portfolio is moderately strong but faces significant revenue risk in 2028 with 1 drug losing exclusivity, including Benzamycin.
Portfolio overview MAYNE PHARMA has a total of 3 drugs in its portfolio, with 1 of them having patents. The company holds 38 active US patents with an average vulnerability score of 70. Notably, there are no expired US patents in the portfolio, and 22 patents are considered vulnerable. The company does not have any biologics in its portfolio.
Cliff calendar 5 drugs lose exclusivity in 2028 including Benzamycin. This year will be a significant cliff for MAYNE PHARMA, with a notable loss of exclusivity for Benzamycin. In addition to Benzamycin, 0 more drugs will lose exclusivity in 2028.
Most exposed drugs Benzamycin is the top drug facing near-term loss of exclusivity, with an earliest active patent expiry date of 2028-02-03 and an average vulnerability score of 70. Unfortunately, the annual revenue for Benzamycin is not available. With 38 patents and a high vulnerability score, Benzamycin poses a significant risk to MAYNE PHARMA's revenue.
Biologic exclusivity MAYNE PHARMA does not have any biologics in its portfolio, which means there are no biologics with BPCIA 12-year reference product exclusivity.
Strategic implications MAYNE PHARMA faces significant revenue risk in the next 5 years, with a total of $0 at risk. To mitigate this risk, the company may consider lifecycle moves such as subQ switches, label extensions, or combination filings to maintain revenue streams.
Loss of exclusivity calendar · next 12 years
Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.
Patent estate by drug
Benzamycin (BENZOYL PEROXIDE)
Cliff 2028 · 2y-
US9868103
Vuln 83
2028-08-08
This patent protects a process for coating solid, water-insoluble particulate matter with a metal oxide layer.
-
US12070629
Vuln 81
2030-12-30
This patent protects a method of using core-stabilized microcapsules that contain at least one active agent encapsulated within an inorganic oxide shell.
-
US9868103
Vuln 75
2028-08-08
This patent protects a process for coating solid, water-insoluble particulate matter with a metal oxide layer.
Patent classification breakdown · active patents
By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.
- Method of Use 31 patents
- Formulation 7 patents
Sources
- FDA Orange Book — small-molecule patents listed against approved NDAs.
- FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
- USPTO Patent Public Search — title, abstract, claim text grounding.
- AI summaries generated by Drug Landscape, grounded in source claim text.
Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.
Track MAYNE PHARMA's patent estate
Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.
↓ CSV export